ARNT and Miyoshi myopathy: They also raise a possibility that targeting ARNT/HIF‐1β might be able to overcome drug resistance in high‐risk MM and RRMM or conferred by microenvironment, in order to improve clinical outcome of those hard‐to‐treat MM patients who currently display poor prognosis due to lack of effective therapy.